# Kraig Biocraft Laboratories, Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [Kraig Biocraft Laboratories, Inc.](/companies/kblb.md) (CIK 1413119)
- Form: 10-Q
- Filed: 2020-11-10
- Accepted by EDGAR: Nov 10, 2020, 16:30 ET
- Period: 2020-09-30
- Accession: 0001493152-20-020935
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1413119/000149315220020935/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1413119/000149315220020935/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $27.6k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-01 to 2020-09-30 | $65.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | −$598.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | −$4.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $94.7k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $279.8k | us-gaap:InterestExpense |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | −$693.2k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | −$4.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | −$994.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2020-09-30 | $43.1k | us-gaap:Cash |
| Current assets | at 2020-09-30 | $56.0k | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $541.0k | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $7.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $7.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-09-30 | −$6.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,845 characters.

FORWARD-LOOKING INFORMATION

The following information should be read in conjunction with Kraig Biocraft Laboratories, Inc. and its subsidiaries (“we”, “us”, “our”, or the “Company”) condensed unaudited financial statements and the notes thereto contained elsewhere in this report. Information in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Form 10-Q that does not consist of historical facts, are “forward-looking statements.” Statements accompanied or qualified by, or containing words such as “may,” “will,” “should,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “anticipates,” “presume,” and “assume” constitute forward-looking statements, and as such, are not a guarantee of future performance.

Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in the “Risk Factors” and detailed in our other Securities and Exchange Commission (“SEC”) filings. Risks and uncertainties can include, among others, international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to obtain sufficient financing to continue and expand business operations; the ability to develop technology and products; changes in technology and the development of technology and intellectual property by competitors; the ability to protect technology and develop intellectual property; and other factors referenced in this and previous filings. Consequently, investors should not place undue reliance on forward-looking statements as predictive of future results.

Because of these risks and uncertainties, the forward-looking events and circumstances discussed in this report or incorporated by reference might not transpire. Factors that cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described elsewhere in this report and in the “Risk Factors” section of our registration statement on Form S-1.

The Company disclaims any obligation to update the forward-looking statements in this report.

### Overview

Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws of Wyoming on April 25, 2006. We were organized to develop high strength fibers using recombinant DNA technology for commercial applications in technical textile. We use genetically engineered silkworms that produce spider silk to create our recombinant spider silk. Applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, and more. We believe that we have been a leader in the research and development of commercially scalable and cost effective spider silk for technical textile. Our primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms. Our business brings twenty-first century biotechnology to the historical silk industry, permitting us to introduce materials with innovative properties and claims into an established commercial ecosystem of silkworm rearing, silk spinning and weaving, and manufacture of garments and other products that can include our specialty fibers and textiles. Specialty fibers are engineered for specific uses that require exceptional strength, flexibility, heat resistance and/or chemical resistance. The specialty fiber market is exemplified by two synthetic fiber products that come from petroleum derivatives: (1) aramid fibers; and (2) ultra-high molecular weight polyethylene fibers. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (*e.g.*, sutures and artificial ligaments), safety and protective clothing and fabrics used in military and aerospace applications (e.g., high-strength composite materials).

We are using genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in our target markets, namely the textile, specialty fiber and technical textile industries.

The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2019 include an explanatory paragraph stating that our net loss from operations and net capital deficiency at December 31, 2019 raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On April 16, 2020, we announced that we successfully developed a new technology platform, based on a non-CRISPR gene editing knock-in knock-out technology. CRISPR is the most recent and efficient gene editing technology1; CRISPR stands for “Clustered regularly interspaced short palindromic repeats.” This is our first knock-in knock-out technology of essentially pure spider silk transgenic. This new system is built on our eco-friendly and cost-effective silkworm production system, which we believe is significantly more advanced than any competing methods. Knock-in knock-out technology allows for the targeting of specific locations and genetic traits for modification, addition, and removal. This new capability will accelerate new product developments, which should allow us to bring products to market more quickly. This capability also allows for genetic trait modifications that were previously impractical, creating opportunities for products outside of silk fibers and increased flexibility in production location. Based on our internal studies, the new technology has a purity rate that is significantly greater than Dragon Silk, a fiber that we developed with our previous tools. Samples of Dragon Silk has already demonstrated to be tougher than many fibers used in bullet proof vests and we expect that the increased spider silk purity, created using this new approach, will yield materials beyond those capabilities. This new system utilizes our eco-friendly and cost-effective silkworm production system, which we believe is significantly more advanced than any of the competing methods. We have already begun the validation process for the first of these new transgenics and anticipate that U.S. production will be possible as early as 2022 or 2023.

This does not affect our current work of overseeing our production facility to ramp up our production of Dragon SilkTM and Monster Silk®, as these fibers are designed to address their own markets.

In August 2019, we received authorization to begin rearing genetically enhanced silkworms at our production facility in Vietnam. We received our investment registration certificate for the facility in April 2018. In October 2019, we delivered the first batch of these silkworms and began operations. These silkworms will serve as the basis for the commercial expansion of our proprietary silk technology. On November 4, 2019, we reported that we had successfully completed rearing the first batch of its transgenic silkworms at the Quang Nam production factory. Seasonal challenges in late December 2019 slowed production operations and the restrictions imposed due to the global pandemic further delayed our operations in 2020 by about 4-6 months. However, we were able to resume production operations of our specialized silk in October 2020, once travel and work restrictions for COVID-19 were lifted. We believe that we will be able to target a capacity of 40 metric tons of our recombinant spider silk fiber per annum from this factory once it reaches maximum utilization. This capacity will allow us to address initial demand for our products and materials for various applications in the protective, performance, and luxury textile markets.

### Plan of Operations

During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:

- We plan to accelerate both our microbiology and selective breeding programs as well as provide more resources for our material testing protocols. We spent approximately $123,050 over the last 12 months on research and development of high strength polymers. In 2019, we directed our research and development efforts on growing our internal capabilities; we plan to continue to dedicate our efforts in 2020/2021 to grow our internal research and development programs.
- We expect to spend approximately $13,700 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. This level of research spending at the university is also a requirement of our licensing agreement with the university.

26

\[1\] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131771/

#### https://www.yourgenome.org/facts/what-is-genome-editing

#### https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting

- We plan to continue the expansion of our production operations at our Quang Nam, Vietnam factory in accordance with our investment and enterprise registration certificates, including the planting of additional mulberry fields in collaboration with local farming cooperatives and the hiring of additional direct staff for our factory as needed.
- We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products; as of the date hereof, we have not had any formal discussion or entered into any definitive agreements regarding any such purchase.
- We will also actively consider pursuing collaborative research opportunities with both private and university laboratories in areas of research which overlap the company’s existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing allows, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
- We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.
- We plan to actively pursue collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in the remainder of 2020 and going forward.
- We plan to actively pursue the development of commercial scale production of our recombinant materials including Monster Silk® and Dragon SilkTM.
- We have initiated and plan to accelerate our efforts for large scale US production. This work will include the research and production of a new transgenic tailored specifically domestic production.

### Limited Operating History

We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process and possible rejection of our products in development.

If financing is not available on satisfactory terms, we may be unable to continue our research and development and other operations. Equity financing will result in dilution to existing shareholders.

### Impact of COVID-19 Outbreak

On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While the closures and limitations on movement, domestically and internationally, are expected to be temporary, if the outbreak continues on its current trajectory the duration of the supply chain disruption could reduce the availability, or result in delays, of materials or supplies to and from the Company, which in turn could materially interrupt the Company’s business operations. As stated above, U.S. travel restrictions impacted our ability to ship eggs to our Vietnam facility and without such eggs, we cannot conduct operations there. In October of 2020, with restrictions lifted, we were able to deliver silkworm eggs to the Vietnam facility and production resumed. Given the speed and frequency of the continuously evolving developments with respect to this pandemic, the Company cannot reasonably estimate the magnitude of the impact to its consolidated results of operations. The Company’s manufacturing facilities support business that have been deemed essential by their respective state governments and remain operational. We have taken every precaution possible to ensure the safety of our employees.

On March 19, 2020, the Company furloughed non-essential staff consistent with leading health official recommendations in order to help prevent the spread of COVID-19. This decision was made in an abundance of caution and primarily impacted staff at our fully owned subsidiary, Prodigy Textiles, in Vietnam and resulted in the temporary closing of silk rearing operations at that facility. As of the date hereof, we have resumed silk production operations at the factory in Vietnam. The temporary suspension of rearing operations resulted in a delay of 4-6 months in the Company’s production expansion schedule. The Company supported its furloughed staff and paid their salaries through June 30, 2020. During the duration of the furlough, the Company CEO did not receive or accrue any pay. On July 1, 2020, furloughed staff returned to work preparing the factory in Vietnam to receive the next shipment of silkworm eggs. On October 24, 2020, silk production operations at the factory resumed. The global pandemic of COVID-19 continues to evolve rapidly, and we will continue to monitor the situation closely, including its potential effect on our plans and timelines.

Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations.

### Three months ended September 30, 2020 compared to the three months ended September 30, 2019

Our revenue, operating expenses, and net loss from operations for the three month period ended September 30, 2020 as compared to the three month period ended September 30, 2019, were as follows – some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

|  | Three Months Ended September 30, 2020 | 2019 | Change | % Change Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| NET REVENUES | $- | $- | - | 0.00% |
| OPERATING EXPENSES: |  |  |  |  |
| General and Administrative | 366,243 | 826,571 | (460,328) | -55.69% |
| Professional Fees | 39,169 | 54,230 | (15,061) | -27.77% |
| Officer’s Salary | 161,861 | 129,577 | 32,284 | 24.91% |
| Rent - Related Party | 3,556 | 2,487 | 1,069 | 42.98% |
| Research and Development | 27,626 | 43,987 | (16,361) | -37.20% |
| **Total operating expenses** | 598,455 | 1,056,852 | (458,397) | -43.37% |
| **Loss from operations** | (598,455) | (1,056,852) | 458,397 | -43.37% |
| Interest expense | (94,703) | (73,276) | (21,427) | 29.24% |
| Interest income | - | 1,640 | (1,640) | 100.00% |
| **Net Loss** | $(693,158) | $(1,128,488) | 435,330 | -38.58% |

28

Net Revenues: During the three months ended September 30, 2020, we realized $0 of revenues from our business. During the three months ended September 30, 2019, we realized $0 of revenues from our business. The change in revenues between the quarter ended September 30, 2020 and 2019 was $0 or 0%.

Cost of Revenues: Costs of revenues for the three months ended September 30, 2020 were $0, as compared to $0 for the three months ended September 30, 2019, a change of $0 or 0%.

Gross Profit: During the three months ended September 30, 2020, we realized a gross profit of $0, as compared to $0 for the three months ended September 30, 2019, a change of $0 or 0%.

Research and development expenses: During the three months ended September 30, 2020, we incurred $27,626 of research and development expenses. During the three months ended September 30, 2019, we incurred $43,987 of research and development expenses, a decrease of $16,361 or 37.20% compared with the same period in 2019. This increase was due to a reduction in research spend.

Professional Fees: During the three months ended September 30, 2020, we incurred $39,169 of professional expenses, which decreased by $15,061 or 27.77% from $54,230 for the three months ended September 30, 2019. This decrease was primarily due to a decrease in professional fees associated with valuation services for the Company’s stock.

Officers Salary: During the three months ended September 30, 2020, officers’ salary expenses increased to $161,861 or 24.91% from $129,577 for the three months ended September 30, 2019.

General and Administrative Expense: General and administrative expenses decreased by $460,328 or 55.69% to $366,243 for the three months ended September 30, 2020 from $826,571 for the three months ended September 30, 2019. Our general and administrative expenses for the three months ended September 30, 2020 consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants issued for services) of $288,450 and office salary of $74,908, for a total of $366,243. Our general and administrative expenses for the three months ended September 30, 2019 consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants issued for services) of $742,461, Travel of $9,404 and office salary of $74,706, for a total of $826,571.

Rent – Related Party: During the three months ended September 30, 2020, rent- related party expense increased to $3,556 or 42.98% from $2,487 for the three months ended September 30, 2019. The rent-related party expense was attributable to the signing on January 23, 2017 the Company signed an eight year property lease with the Company’s President.

Interest Expense: Interest expense increase by $21,427 to $94,703 for the three month period ended September 30, 2020 from $73,276 for the three month period ended September 30, 2019. The increase was primarily due to interest on certain Company loans.

Interest Income: Interest income decreased by $1,640 to $0 for the three month period ended September 30, 2020 from $1,640 for the three month period ended September 30, 2019. The decrease was primarily due to interest on bank accounts.

Net Loss: Net loss decreased by $435,330, or 38.58 %, to a net loss of $693,158 for the three month period ended September 30, 2020 from a net loss of $1,128,488 for the three month period ended September 30, 2019. This increase in net loss was primarily attributable to both increases in general and administrative expenses.

### Nine months ended September 30, 2020 compared to the nine months ended September 30, 2019

Our revenue, operating expenses, and net loss from operations for the nine month period ended September 30, 2020 as compared to the nine month period ended September 30, 2019, were as follows – some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

|  | Nine Months Ended September 30, 2020 | 2019 | Change | % Change Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| NET REVENUES | $- | $- | - | 0.00% |
| OPERATING EXPENSES: |  |  |  |  |
| General and Administrative | 3,507,302 | 1,066,724 | 2,440,578 | 228.79% |
| Professional Fees | 89,643 | 242,458 | (152,815) | -63.03% |
| Officer’s Salary | 361,276 | 395,782 | (34,506) | -8.72% |
| Rent - Related Party | 9,819 | 11,913 | (2,094) | -17.58% |
| Research and Development | 65,408 | 87,228 | (21,820) | -25.01% |
| **Total operating expenses** | 4,033,448 | 1,804,105 | 2,229,343 | 123.57% |
| **Loss from operations** | (4,033,448) | (1,804,105) | (2,229,343) | 123.57% |
| Interest expense | (279,846) | (210,891) | (68,955) | 32.70% |
| Interest income | - | 6,265 | (6,265) | 100.00% |
| **Net Loss** | $(4,313,294) | $(2,008,731) | (2,304,563) | 114.73% |

Net Revenues: During the nine months ended September 30, we realized $0 of revenues from our business. During the nine months ended September 30, 2019, we realized $0 of revenues from our business. The change in revenues between the quarter ended September 30, 2020 and 2019 was $0 or 0%.

Cost of Revenues: Costs of revenues for the nine months ended September 30, 2020 were $0, as compared to $0 for the nine months ended September 30, 2019, a change of $0 or 0%.

Gross Profit: During the nine months ended September 30, 2020, we realized a gross profit of $0, as compared to $0 for the nine months ended September 30, 2019, a change of $0 or 0%.

Research and development expenses: During the nine months ended September 30, 2020, we incurred $65,408 of research and development expenses. During the nine months ended September 30, 2019, we incurred $87,228 of research and development expenses, a decrease of $21,820 or 25.01% compared with the same period in 2019. This decrease was due to a reduction in research spend.

Professional Fees: During the nine months ended September 30, 2020, we incurred $89,643 of professional expenses, which decreased by $152,815 or 63.03% from $242,458 for the nine months ended September 30, 2019. This decrease was primarily due to a decrease in professional fees associated with valuation services for the Company’s stock.

Officers Salary: During the nine months ended September 30, 2020, officers’ salary expenses decreased to $361,276 or 8.72% from $395,782 for the nine months ended September 30, 2019.

General and Administrative Expense: General and administrative expenses increased by $2,440,578 or 228.79% to $3,507,302 for the nine months ended September 30, 2020 from $1,066,724 for the nine months ended September 30, 2019. Our general and administrative expenses for the nine months ended September 30, 2020 consisted of other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants issued for services) of $3,4485,316, Travel of $2,900 and office salary of $19,086 for a total of $3,507,302. Our general and administrative expenses for the nine months ended September 30, 2019 consisted of consulting fees of $5,787 and other general and administrative expenses (which includes expenses such as auto, business development, SEC filings, investor relations, general office, warrants issued for services) of $868,609, Travel of $24,170 and office salary of $168,158, for a total of $1,066,724.

Rent – Related Party: During the nine months ended September 30, 2020, rent- related party expense decreased to $9,819 or 17.58 % from $11,913 for the nine months ended September 30, 2019. The rent-related party expense was attributable to the signing on January 23, 2017 the Company signed an eight year property lease with the Company’s President.

Interest Expense: Interest expense increase by $68,955 to $279,846 for the nine month period ended September 30, 2020 from $210,891 for the nine month period ended September 30, 2019. The increase was primarily due to interest on certain Company loans.

Interest Income: Interest income decreased by $6,265 to $0 for the nine month period ended September 30, 2020 from $6,265 for the nine month period ended September 30, 2019. The decrease was primarily due to interest on bank accounts.

Net Loss: Net loss increased by $2,304,563, or 114.738 %, to a net loss of $4,313,294 for the nine month period ended September 30, 2020 from a net loss of $2,008,731 for the nine month period ended September 30, 2019. This increase in net loss was primarily attributable to both increases in general and administrative expenses and a decrease in revenues.

### Capital Resources and Liquidity

Our financial statements have been presented on the basis that are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the financial statements, we incurred a net loss of $4,313,294 during the nine months ended September 30, 2020, and losses are expected to continue in the near term. The accumulated deficit is $34,111,200 at September 30, 2020. Refer to Note 2 for our discussion of stockholder deficit. We have been funding our operations through private loans and the sale of common stock in private placement transactions. Refer to Note 6 and Note 7 in the financial statements for our discussion of notes payable and shares issued, respectively. Our cash resources are insufficient to meet our planned business objectives without additional financing. These and other factors raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.

Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. At September 30, 2020, we had $43,062 of cash on hand. These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in the case of equity financing.

Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts. There can be no assurance that the Company can successfully accomplish these steps and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing. There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all. As of the date of this Report, we have not entered into any formal agreements regarding the above.

In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.

Cash, total current assets, total assets, total current liabilities and total liabilities as of September 30, 2020 as compared to December 31, 2019, were as follows:

|  | September 30, 2020 | December 31, 2019 |
| --- | ---: | ---: |
| Cash | $43,062 | $125,024 |
| Prepaid expenses | $12,979 | $31,745 |
| Total current assets | $56,041 | $156,769 |
| Total assets | $541,039 | $750,850 |
| Total current liabilities | $6,964,563 | $5,584,383 |
| Total liabilities | $7,381,121 | $6,138,908 |

At September 30, 2020, we had a working capital deficit of $6,908,522 compared to a working capital deficit of $5,427,614 at December 31, 2019. Current liabilities increased to $6,964,563 at September 30, 2020 from $5,584,383 at December 31, 2019, primarily as a result of primarily as a result of accounts payable, note payable and accrued compensation.

For the nine months ended September 30, 2020, net cash used in operations of $994,557 was the result of a net loss of $4,313,294 offset by offset by depreciation expense of $21,277, options issuance of $2,804,794, imputed interest on related party loans of $38,981, decrease in prepaid expenses of $18,766 and a decrease in operating lease right of use of $87,806, an increase of accrued expenses and other payables-related party of $469,268, decrease in accounts payable of $40,538 and a decrease in operating lease liabilities of $81,617. For the nine months ended September 30, 2019, net cash used in operations of $769,583 was the result of a net loss of $2,008,731 offset by offset by depreciation expense of $22,448, warrants cancellation and issuance an cancellation of $19,915, options issuance to related parties of $ 584,776, imputed interest on related party loans of $16,027, increase in prepaid expenses of $5,812 and a decrease in operating lease right of use of $58,123, an increase of accrued expenses and other payables-related party of $541,175, an increase in accounts payable of $95,927 and a decrease in operating lease liabilities of $53,601.

Net cash used in our investing activities were $0 and $72,966 for the nine months ended September 30, 2020 and September 30, 2019, respectively. Our investing activities for the nine months ended September 30, 2019 are attributable to purchases of fixed assets.

Our financing activities resulted in a cash inflow of $912,595 for the nine months ended September 30, 2020, which is represented by $45,000 loan repayment, $850,000 proceeds from a shareholder note payable, $17,495 contributed capital from a shareholder and $90,100 proceeds from the SBA Paycheck Protection Loan. Our financing activities resulted in a cash inflow of $1,112,000 for the nine months ended September 30, 2019, which is represented by $1,000,000 proceeds from issuance of common stock, $8,000 loan repayment and $120,000 proceeds from shareholder note payable.

### Critical Accounting Policies

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2019, for disclosures regarding the Company’s critical accounting policies and estimates, as well as updates further disclosed in our interim financial statements as described in this Form 10-Q.

### Recent Accounting Pronouncements

In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods within that fiscal year. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 effective April 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, *Leases*. The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The Company adopted the new lease guidance effective January 1, 2019 using the modified retrospective transition approach, applying the new standard to all of its leases existing at the date of initial application which is the effective date of adoption. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. We elected the package of practical expedients which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We did not elect the hindsight practical expedient which permits entities to use hindsight in determining the lease term and assessing impairment. The adoption of the lease standard did not change our previously reported consolidated statements of operations and did not result in a cumulative catch-up adjustment to opening equity. As a result, the Company has recorded Right-to-use assets and corresponding Lease obligations as more fully discussed in Note 4.

All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as “special purpose entities” (SPEs).

## Controls and procedures

As filed, 3,487 characters.

#### Evaluation of Disclosure Controls and Procedures

As of the end of our fiscal quarter ended September 30, 2020, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon those evaluations, management concluded that our disclosure controls and procedures were not effective as of September 30, 2020, to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Going forward from this filing, the Company intends to work on establishing and maintaining disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

#### Changes in Internal Control over Financial Reporting

During the quarter covered by this Report, there were no changes in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. Although we continue to educate our management personnel to increase to increase its ability to comply with the disclosure requirements and financial reporting controls and management oversight of accounting and reporting functions in the future, as we stated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, we do not expect to remediate the weaknesses in our internal controls over financial reporting until the time when we start to commercialize a recombinant fiber or such time as we have sufficient cash flow to carry out our remediation plans.

## Risk factors

As filed, 173 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item.

Filed Nov 10, 2020.
Source: SEC EDGAR, the filing index for accession 0001493152-20-020935. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
